Determinants of pharmaceutical expenditures on cardiovascular diseases

• Název v anglickém jazyce: Determinants of pharmaceutical expenditures on cardiovascular diseases
• Klíčová slova anglicky: Pharmaceutical expenditures, cardiovascular diseases, GDP, health expenditure, fixed effect model, prevalence of a disease, aging of population.
• Akademický rok vypsání: 2011/2012
• Typ práce: diplomová práce
• Jazyk práce: angličtina
• Ústav: Institut ekonomických studií (23-IES)
• Vedoucí / školitel: Mgr. Radovan Chalupka, Ph.D.
• Řešitel: skrytý - zadáno vedoucím/školitelem
• Datum přihlášení: 10.06.2011
• Datum zadání: 10.06.2011
• Datum a čas obhajoby: 30.01.2013 00:00
• Místo konání obhajoby: IES
• Datum odevzdání elektronické podoby: 06.01.2013
• Datum proběhlé obhajoby: 30.01.2013
• Oponenti: PhDr. Mgr. Jana Votápková, Ph.D.

Seznam odborné literatury

Baltagi, B.H., (1995) “Econometric Analysis of Panel Data”. New York: John Wiley & Sons, Ltd.
Baltagi, B.H., (2002) ”Econometrics” 3rd Edition, pp. 307-319.
Baltagi, B.H., (2002), Recent Developments in the Econometrics of Panel Data, Volumes I and II (Edward Elgar Publishing, Cheltenham).
"Before the Storm" Chemical & Engineering News 89 (49): 12–18. 2011.
Bebchuk, L. A. and Fried, J. (2004) “Pay without Performance: The Unfulfilled Promise of Executive Compensation” Harvard University Press
Berndt, E. (2001) “The U.S. Pharmaceutical Industry: Why Major Growth In Times of Cost Containment?” Health Affairs 20: 100-114.
Bridget B. Kelly (2010) “Promoting Cardiovascular Health in the Developing World”, Institute of Medicine; Fuster, Valentin
Brüderl, J. (2005) “Panel Data Analysis” University of Mannheim, March 2005
Büscher, A. Sivertsen, B. and White, J. (2009) “Nurses and Midwives: A force for health” Survey on the situation of nursing and midwifery in the Member States of the European Region of the World Health Organization
Busse, R. Ёgg S. J. and Henke, K.D. (2005) “Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures?” international journal of health planning and management 20: 329–349
Calfee, J. (2004) “Prices, Markets and the Pharmaceutical Revolution” Washington, DC: AEI Press.
Civan, A. and Koeksal, B. (2009) “The effect of newer drugs on health spending: Do they really increase the costs?” Health Economics 19: 581–595
Cleanthous, P. (2011) “Evaluating innovation and moral hazard in pharmaceuticals” department of economics university of Cyprus, Discussion Paper 03-2011
Clemente, J. Marcuello, C. and Montaes, A. (2008) “Pharmaceutical expenditure, total health-care expenditure and GDP” Health Economics 17: 1187–1206
Cremiuex P, Meilleur M, Ouellette P, Petit P, Zelder M, Potvin K. (2005) “Public and private pharmaceutical spending as determinants of health outcomes in Canada” Health Economics 14: 107–116
Christopher, D. (2007) Introduction to Econometrics, Third Edition, Oxford University Press.
Danzon, M. P. and Soumerai B. S. (2002) “Pharmaceuticals: Access, Cost, Pricing,and Directions for the Future” Center for Policy Research Policy Briefs No. 23
Danzon, P. M. and Towse, A. (2003) “Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents” AEI-Brookings Joint Center publications Working Paper 03-7
Danzon, M. P. and Keuffel, L. E. (2007) “Regulation of the Pharmaceutical-Biotechnology Industry” The Wharton School, University of Pennsylvania,PA, 19104-6218.
Danzon, M. P. Mulcahy, W. A. and Towse, K. A. (2011) “Pharmaceutical pricing in emerginf markets: effects of income, competition and procurement” NBER working paper 17174
Dickson, M. and Jacobzone, S. (2003), “Pharmaceutical Use and Expenditure for Cardiovascular Disease and Stroke: A Study of 12 OECD Countries”; OECD health working papers No. 1
Dictionary.com, Unabridged (v 1.1), Random House, Inc., via dictionary.com. Retrieved on 15.11.2012
Dubois, R. W. Chawla, A. J. Neslusan, C. A. Smith, M. W. and Wade, S. (2000) “Explaining drug spending trends: does perception match reality” Health Affairs, 19, no.2 (2000):231-239
Finkelstein, Temin (2008) "Reasonable Rx: Solving the Drug Price Crisis” Financial Times Press, Pearson Education (US), United States.
Health trends in the EU, (2010) the Health Network at the request of European Commission, DG Employment, Social Affairs and Equal Opportunities.
Halpin H.A. Morales-Suárez-Varela M.M. Martin-Moreno, J.M.(2010) “Chronic disease prevention and the New Public Health” Public Health Reviews, 32:120-154.
Hausman, Jerry A. Taylor, William E. (1981): Panel Data and Unobservable Individual Effects, Econometrica 49: 6, 1377-1398.
Have, A. Canoy, M.F.M. Nelissen, E.Gorp, N. Meindert, L. Thio, V. and Plaisier, N. (2009) “Competitiveness of the EU Market and Industry for Pharmaceuticals”, European Commission, Directorate General Enterprise & Industry.
Heffler, S. Smith, S. Keehan et al., “U.S. Health Spending Projections for 2004–2014, Health Affairs Web Exclusive (Feb. 23, 2005): W5-74–W5-85.
Johnston, J. and J. Dinardo (1997). Econometric methods, 4th edition, McGraw Hill, New York.
Kaufman, D. W., J. P. Kelly, L. Rosenberg, T. E. Anderson, and A. A. Mitchell. (2002). “Recent Patterns of Medication Use in the Ambulatory Adult Population of the United States” Journal of the American Medical Association 282: 337-344.
Kildemoes H, Christiansen T, Gyrd-Hansen D, Kristiansen I, Andersen M. (2006) “The impact of population aging on future Danish drug expenditure” Health Policy 75: 298–311
Lu, Z. J. and Comanor, W. (1998). “Strategic Pricing of New Pharmaceuticals,” Review of Economics and Statistics, 80(1), 108-118.
Lundin, D. (2000). “Moral Hazards in Physician Prescription Behavior” Journal of Health Economics 19: 639-62.
Maton, A. (1993). Human Biology and Health. Englewood Cliffs, New Jersey: Prentice Hall. ISBN 0-13-981176-1.
Market definition in the pharmaceutical sector (2006) Charles River Associates, November
McKenzie, J., Neiger, B., Thackeray, R. (2009). “Health Education and Health Promotion. Planning, Implementing, & Evaluating Health Promotion Programs”. (pp. 3-4). 5th edition. San Francisco, CA: Pearson Education, Inc.
McLeod, L., Bereza, B.G., Shim, M., & Grootendorst, P. (2011). “Financial burden of household out-of- pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data”. Open Medicine, 5(1).
Mintzes, B. Lexchin, J. (2005) “Do higher drug costs lead to better health?”, Canadian journal of Clinical Pharmacology, Volume 12(1).
Morgan, S. and C. Cunningham (2011) “Population aging and the determinants of health care expenditures: the case of hospital, medical, and pharmaceutical care in British Columbia, 1996 to 2006” Healthcare Policy 7(1): 68-79
Morgan S.G. (2005), “Booming prescription drug expenditure: a population-based analysis of age dinamycs”; Medical care volume 43 iss, 10 pp.996-1008
Moroney, S.D. and Kual, A. (2003) “Understanding Health Care Cost Drivers”; National Institute of Health Policy
Nichols, M. Townsend, N. Scarborough, P. Rayner, M. Leal J. Luengo-Fernandez, R. and Gray, A. (2008), European cardiovascular disease statistics European Heart Network.
OECD (2003b), “Agricultural policies in OECD countries: monitoring and evaluation” 2003, Paris.
OECD (2011), Health at a Glance 2011: OECD Indicators, OECD Publishing.
OECD health data (2012). Economic outlook No. 85
Okunade A, Suraratdecha C. (2006) “The pervasiveness of pharmaceutical expenditures inertia in the OECD countries” Social Science and Medicine 63: 225–238
Reinhardt, U. E. (2001) “Perspectives on the Pharmaceutical Industry”. Health Affairs 20: 136-149.
Scherer, P. and M. Devaux (2010), “The Challenge of Financing Health Care in the Current Crisis: An Analysis Based on the OECD Data”, OECD Health Working Papers, No. 49, OECD Publishing.
Schmidheiny, K. (2012) Short Guides to microeconomic, University at Basel
Schweitzer, S.O. (1997) “Pharmaceutical economics and policy” New York: Oxford University Press, pp 73-85
Sisto, A. and Zanola, R., (2005) "The Determinants of Public Pharmaceutical Expenditures: Does Italian Health Federalism Impact on Them?"
Thomas, C.P.G. Ritter, and S. S. Wallack. (2001) “Growth in Prescription Drug Spending Among Insured Elders” Health Affairs 20: 265-77.
The World Bank data (2012)
Vandegrift, D. and Datta, A. (2006). "Prescription Drug Expenditures in the United States: The Effects of Obesity, Demographics, and New Pharmaceutical Products," Southern Economic Journal, Southern Economic Association, vol. 73(2), pages 515�529, October.
Wallace, T.D. and A. Hussain, (1969), The use of error components models in combining crosssection and time-series data, Econometrica 37, 55-72.
WHO, “Evaluation of recent changes in the financing of health services: Report of a WHO study group”. Geneva: World Health Organization; 1993: 1-74. WHO Technical Report Series, N° 829.
Winkleby M.A. et al.,(1992) “Socioeconomic Status and Health: How Education, Income, and Occupation Contribute to Risk Factors for Cardiovascular Disease,” American Journal of Public Health 82, no. 6 (1992): 816–820.
Zweifel, P. Breyer, F. Kifmann, M. (2009) “The market of pharmaceuticals” Health Economics, 2009, second edition, PP 400-4002
Zweifel, P., F. Breyer and M. Kifmann (2009), Health Economics, 2nd edition, Springer-Verlag, Berlin and Heidelberg

Předběžná náplň práce

The thesis analyzes the determinants of pharmaceutical expenditures on cardiovascular diseases with particular focus on Central Europe. We show how the pharmaceutical expenditure varies across the countries. We try to empirically verify that factors such as age, GDP, total health expenditure, education and prevalence of a particular disease cause the variation. Applying the fixed effect model on selected countries in the period 2000–2009, we find that the increase in pharmaceutical expenditures on cardiovascular diseases is explained mainly by aging population and prevalence of the diseases. Additionally, countries with higher GDP tend to also have somewhat higher pharmaceutical expenditures on cardiovascular diseases.

Předběžná náplň práce v anglickém jazyce

The thesis analyzes the determinants of pharmaceutical expenditures on cardiovascular diseases with particular focus on Central Europe. We show how the pharmaceutical expenditure varies across the countries. We try to empirically verify that factors such as age, GDP, total health expenditure, education and prevalence of a particular disease cause the variation. Applying the fixed effect model on selected countries in the period 2000–2009, we find that the increase in pharmaceutical expenditures on cardiovascular diseases is explained mainly by aging population and prevalence of the diseases. Additionally, countries with higher GDP tend to also have somewhat higher pharmaceutical expenditures on cardiovascular diseases.